Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revive Therapeutics Ltd. C.RVV

Alternate Symbol(s):  RVVTF

Healthcare
Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is... see more

Recent & Breaking News (CSE:RVV)

This life sciences company is gearing up to treat long COVID

Jocelyn Aspa April 25, 2024

Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID

GlobeNewswire April 23, 2024

Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product

GlobeNewswire April 18, 2024

Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder

GlobeNewswire April 2, 2024

Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID

GlobeNewswire March 27, 2024

Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID

GlobeNewswire March 19, 2024

Revive Therapeutics Provides Corporate Update

GlobeNewswire March 12, 2024

Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110

GlobeNewswire February 26, 2024

Revive Therapeutics Explores the Use of Bucillamine for Long COVID

GlobeNewswire February 1, 2024

Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500

GlobeNewswire January 31, 2024

Revive Therapeutics Ltd. Announces Offering of Up to $3 Million

GlobeNewswire January 24, 2024

Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada

GlobeNewswire January 16, 2024

Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine

GlobeNewswire January 10, 2024

Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders

GlobeNewswire December 20, 2023

Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillamine

GlobeNewswire December 18, 2023

Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development

GlobeNewswire November 21, 2023

Revive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test

GlobeNewswire November 6, 2023

Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure

GlobeNewswire October 17, 2023

Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development

GlobeNewswire October 11, 2023

Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development

GlobeNewswire August 22, 2023